AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03027011 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Control group without remote ischemic preconditioning
Study NCT05037344 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral psychotherapy
Description: The goal is to develop an internet and smart phone delivered CBT (iCBT) for the treatment of pediatric OCD on the bases of our feasibility study. This group will start directly with therapy of 16 weeks. The waiting group gets the same intervention after 16 weeks of waiting.
Study NCT05037344 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive-behavioral psychotherapy
Description: The goal is to develop an internet and smart phone delivered CBT (iCBT) for the treatment of pediatric OCD on the bases of our feasibility study. This group will start directly with therapy of 16 weeks. The waiting group gets the same intervention after 16 weeks of waiting.
Study NCT03794180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TJ003234
Description: Brownish-yellow liquid containing TJ003234, a recombinant humanized immunoglobulin (Ig) G1 monoclonal antibody diluted with normal saline
Study NCT03794180 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Colorless to slightly brownish-yellow liquid without TJ003234 diluted with normal saline
Study NCT00366353 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Sedation during SBT
Study NCT00366353 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No sedation
Study NCT02665130 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tai-chi plus Indacaterol
Description: Participants perform Tai-chi exercise 5 days/week and take indacaterol 150ug/day for 24 weeks
Study NCT02665130 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Pulmonary rehabilitation plus Indacaterol
Description: Participants perform conventional exercise 5 days/week and take indacaterol 150ug/day for 24 weeks
Study NCT00943735 — intervention group
Intervention type: DRUG
Intervention: Fesoterodine
Description: Fesoterodine 4 mg and 8 mg QD
Study NCT00943735 — intervention group
Intervention type: BEHAVIORAL
Intervention: Your Way
Description: early intervention after treatment initiation and before patients have an opportunity to discontinue medication; reinforcing the treatable nature of OAB
Study NCT02768649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risperidone
Description: All eligible subjects received a test dose of risperidone to ensure tolerability prior to dosing with RBP-7000.
Study NCT01082718 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mefloquine Artesunate
Description: Mefloquine-artesunate fixed dose combination (Farmanguinhos): Artesuanto 100 mg and Mefloquine 220mg per tablet, dosed once daily for 3 days such that mefloquine dose is approximately 8mg/kg/day.
Study NCT01082718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mefloquine Artesunate
Description: Mefloquine-artesunate fixed dose combination (Farmanguinhos): Artesuanto 100 mg and Mefloquine 220mg per tablet, dosed once daily for 3 days such that mefloquine dose is approximately 8mg/kg/day.
Study NCT00819533 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sensor (ActiSight™ Needle Guidance System)
Description: Patients will have their lung sample obtained under CT and ActiSight needle guidance system
Study NCT04132024 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT-I)
Description: CBT-I has a specific protocol with behavioral targets that differ significantly from standard CBT. This approach focuses on implementing sleep restriction and stimulus control interventions which are fully deployed during the first session. 5 CBT-I sessions will be delivered over the course of 8 weeks. Key recommendations include: 1) reduce time in bed; 2) get up at the same time every day; 3) do not go to bed unless sleepy; 4) do not stay in bed awake for more than 15 minutes; and 5) avoid napping. Participants are also taught relaxation strategies and cognitive therapy addresses arousal and catastrophizing.
Study NCT03920826 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial alternating current stimulation
Description: The alternating current is administered through medical grade conductive pads that are produced specifically for the Nexalin technology. The pads are places on the forehead and behind each ear, and are connected to the Nexalin device with thin cables. Intervention will be implemented with a tACS device with gamma-frequency (40 Hz) and a peak-to-peak amplitude of 15mA, 30 one-hour sessions in 3 weeks (21 days).
Study NCT03531853 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hand-held swept source optical coherence tomography
Description: images the eye
Study NCT02054455 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus paracasei F19
Description: 25x10E9 live bacterial cells for 3 days/week for 6 months
Study NCT02054455 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo will consist of a preparation similar to that of probiotic but with no added microorganisms.
Study NCT02054455 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will consist of a preparation similar to that of probiotic but with no added microorganisms.
Study NCT04602052 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dilation and evacuation
Description: Abortion is termination of pregannacy by evaccuating the uterus using either medical or surgical technique
Study NCT04602052 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dilation and evacuation
Description: Abortion is termination of pregannacy by evaccuating the uterus using either medical or surgical technique
Study NCT04795050 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project POWER
Description: Diabetes health promotion/cardiovascular disease risk reduction educational curriculum
Study NCT02556892 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Participants will self-administer 420 milligram (mg) oral ibrutinib once daily continuously from Cycle 1 to Cycle 6 and thereafter every 28 days until treatment discontinuation.
Study NCT04126954 — intervention group
Intervention type: OTHER
Intervention: Serum PTH concentrations results
Description: To compare serum PTH concentrations results in patients with primary or secondary hyperPTH resulting from phosphocalcic pathology before and three months after initiation of cinacalcet therapy.
Study NCT00697216 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HBV-MPL vaccine 208129
Description: 2-dose intramuscular injection
Study NCT00697216 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Engerix™-B
Description: 3-dose intramuscular injection
Study NCT00699478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mecobalamin
Description: Methycobal Tab 0.5mg (contains 0.5 mg mecobalamin) for 3 times a day (Q8hrs) for three months
Study NCT00627471 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glargine
Description: For the control group (following the physician's standard practice) a minimum of 4 visits to the clinic is required. Insulin titration and concomitant medications will be done at the discretion of the physician. Strips will be distributed among patients in this group, but there will not be a requirement in frequency or type of SMBG.
Study NCT00627471 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glargine
Description: In the group following the algorithm, fasting SMBG will be asked 3 times a week until FBG\<100 mg/dl is achieved. Afterwards, 1 fasting SMBG will be asked weekly. Pre-prandial SMBG will be performed at the discretion of the physician.~For the group following the algorithm, during the titration period, weekly telephone contacts will be required and a minimum of 4 visits to the clinic.
Study NCT02873156 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2027
Description: Participants will receive E2027 capsules, orally once daily (QD) on Days 1 to 14 after an overnight fast of at least 10 hours. E2027 will be administered orally with 240 milliliter (mL) (8 fluid ounces) of water.
Study NCT02873156 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: E2027 matched placebo
Description: Participants will receive E2027 matched placebo capsules, orally once daily (QD) on Days 1 to 14 after an overnight fast of at least 10 hours. E2027 matched placebo will be administered orally with 240 mL (8 fluid ounces) of water.
Study NCT03386773 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 16-week program
Description: 16-week program where patients will receive regular health promotion messaging about (a) food, nutrition, and diet; and (b) exercise and physical activity.
Study NCT03386773 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 16-week program
Description: 16-week program where patients will receive regular health promotion messaging about (a) food, nutrition, and diet; and (b) exercise and physical activity.
Study NCT03386773 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient generated health data
Description: Intervention patients will be asked to track patient generated health data and patient reported outcomes. PGHD elements related to weight management will be collected through a mobile health app loaded on their phones and/or through using a fitness tracker, depending on patient preference, and to share that information with the research team. Patient-reported outcomes (PRO) measures will be collected pre-and-post-intervention. Intervention patients will also be asked to provide answers to patient-reported outcomes measures on a weekly basis.
Study NCT03274778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib 20 MG
Description: tablets
Study NCT03573258 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fiber or Placebo (depending on the randomization)
Description: ingestion of dietary fibers prior to meal intake
Study NCT03573258 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Fiber or Placebo (depending on the randomization)
Description: ingestion of dietary fibers prior to meal intake
Study NCT02909049 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MIDAZOLAM
Description: Intravenous bolus anesthesia 5 minutes previous to saturation prostate biopsy.
Study NCT02909049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEPIVACAÍNE
Description: Local periprostatic anesthesia infiltration, previous to saturation prostate biopsy.
Study NCT02909049 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FENTANILE
Description: Intravenous bolus anesthesia 3 minutes previous to saturation prostate biopsy.
Study NCT02909049 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: KETAMINE
Description: Intravenous bolus anesthesia 1 minute previous to saturation prostate biopsy.
Study NCT02393716 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Endurant Evo AAA Stent Graft System
Study NCT02393716 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Endovascular aneurysm repair (EVAR)
Study NCT02306343 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: InsuPad
Description: The InsuPad device is composed of a disposable heating pad and a reusable control unit. The heating pad is intended for one day use. The user would attach the InsuPad device to a site where insulin can be injected. When there is a need for insulin bolus injection the user would inject the insulin to a location designate for that. The device would start heating the area around the injection site without over heating the insulin. At the end of the day the subject would remove the device, dispose of the disposable unit and put the reusable unit for recharging.
Study NCT03097016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-122
Description: All subjects will receive one 3 mg CC-122 capsule the morning of Day 1 which will be administered in the fasted state.
Study NCT03801551 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Validate according to psychometric criteria, a dimensional measure of apathy in a population suffering from schizophrenia spectrum disorder and other psychotic disorders (according to DSM-5 criteria).
Description: Validate according to psychometric criteria, a dimensional measure of apathy in a population suffering from schizophrenia spectrum disorder and other psychotic disorders (according to DSM-5 criteria).
Study NCT01320280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBW 2992 (Afatinib)
Description: 50 mg BIBW 2992 (Afatinib) tablets daily continuously
Study NCT03122704 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: GBS screening
Description: Vaginal and anal swabs of patients will be screened for GBS screening
Study NCT00758602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: 0.75-1 g PO BID from Day 0 through Month 12
Study NCT00758602 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mycophenolate mofetil
Description: 0.75-1 g PO BID from Day 0 through Month 12
Study NCT00758602 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tacrolimus, standard dose
Description: Initial dose of 0.1-0.15 mg/kg PO BID to reach a target trough dose of 8-10 ng/mL from Day 0 through Month 3; the dose was adjusted to reach a target trough level of 7-10 ng/mL in Month 3 and continued through Month 12.
Study NCT03920826 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham stimulation
Description: Electrodes will also be put on patient's forehead and behind each ear. The sham stimulator has the exactly same appearance with the true stimulator. Participants and operators cannot determine whether the stimulator is true based on its appearance or patients' feelings. However, when the device is started, no current flows through the electrodes. Participants in this controlled group will also receive sham stimulations with 30 one-hour sessions in 21 days.
Study NCT03167086 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Empowered Relief (ER)
Description: Empowered Relief (ER): A single-session skills-based approximately 2-hr group intervention to treat chronic pain.~Format of intervention: Therapist-delivered PowerPoint presentation with experiential exercises. Experienced senior level psychologist and two (2) additional doctoral level psychologists will conduct the ER sessions.~Content of intervention: ER Participants have the 'ER Relaxation Resource' app (guided relaxation audiofile) loaded on their apple or android electronic device.
Study NCT03167086 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT)
Description: Format of intervention: 8-week Manualized Pain-CBT Group Intervention will be delivered by PhD-level psychotherapists (3 in total). The group is run weekly for 8 consecutive classes. Each class is 2 hours with a midpoint break (16 hours total intervention time).~Content of intervention: The protocol and materials were developed with funding from NIH/NCCAM R01 AT006226 (Dan Cherkin, PI) \[1\& 2\], and include content from a pain-CBT program developed by Drs. Ehde, Dillworth, and Turner \[3\].~Participants receive a workbook with homework and a copy of The Pain Survival Guide: How to reclaim your life © 2005 by Turk \& Winter \[4\] for optional reading.
Study NCT03167086 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education (HE)
Description: Format of intervention: The HE class will be instructor taught and will involve a PowerPoint presentation and handouts. Two additional providers will be identified and trained to conduct the sessions. Selected instructors will have substantial health education experience.~Content of intervention: HE content will include basic information such as nutrition and interacting with the healthcare system; these relatively 'inert' topics are unlikely to impart any specific effects typically found with a true psychobehavioral intervention.
Study NCT02292121 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intestinal permeability
Description: 5h-intestinal permeability test 10-hour overnight fasting subject who first emptied his bladder drinks a solution of mannitol and lactitol. 2 hours after, the subject drinks 500mL of water in less than 30 minutes. All urine samples are collected during the 5h-test for measurement of lactitol and mannitol.
Study NCT02292121 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intestinal permeability
Description: 5h-intestinal permeability test 10-hour overnight fasting subject who first emptied his bladder drinks a solution of mannitol and lactitol. 2 hours after, the subject drinks 500mL of water in less than 30 minutes. All urine samples are collected during the 5h-test for measurement of lactitol and mannitol.
Study NCT02634918 — intervention group
Intervention type: OTHER
Intervention: ultrasound
Description: ultrasound will be performed in hemophilia boys with a history of 20 joint bleeds- Group I, less than 2 joint bleeds into a joint -Group II and no joint bleeds- Group III
Study NCT01427491 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Aquacel® Ag
Description: Dressing will be changed during the clinic visit on day 3, 7 and 14. In between the clinic visits the dressing should be changed when needed depending on the clinical condition of the wound and the volume of exudate.
Study NCT01427491 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mepilex® Border Ag
Description: Dressing will be changed during the clinic visit on day 3, 7 and 14. In between the clinic visits the dressing should be changed when needed depending on the clinical condition of the wound and the volume of exudate.
Study NCT02300545 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Study NCT01726764 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: St John's Wort
Study NCT01204658 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal vaccine GSK 2189242A (LD formulation 1)
Description: Intramuscular injection
Study NCT01204658 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal vaccine GSK 2189242A (HD formulation 2)
Description: Intramuscular injection
Study NCT01204658 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Synflorix
Description: Intramuscular injection
Study NCT00758602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus, low dose
Description: Initial dose of 0.1-0.15 mg/kg PO BID to reach a target trough dose of 8 to 10 ng/mL from Day 0 through Month 3; 0.05-0.08 mg/kg PO BID to reach a target trough dose of 2-5 ng/mL in Month 3 and continued through Month 12.
Study NCT00758602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: corticosteroids
Description: According to center's practice
Study NCT04363164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone cypionate
Description: Depo-Testosterone Injection, for intramuscular injection, contains testosterone cypionate which is the oil-soluble of the androgenic hormone testosterone. Testosterone cypionate is a white or creamy white crystalline powder, odorless or nearly so and stable in air. Depo-Testosterone Injection is available in two strengths, 100 mg/mL and 200 mg/mL testosterone cypionate.
Study NCT04363164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Enzalutamide is a white crystalline non-hygroscopic solid. It is practically insoluble in water. Enzalutamide is provided as liquid-filled soft gelatin capsules for oral administration. Each capsule contains 40 mg of enzalutamide as a solution in caprylocaproyl polyoxylglycerides. The inactive ingredients are caprylocaproyl polyoxylglycerides, butylated hydroxyanisole, butylated hydroxytoluene, gelatin, sorbitol sorbitan solution, glycerin, purified water, titanium dioxide, and black iron oxide.
Study NCT04363164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone enanthate
Description: Testosterone Enanthate Injection, for intramuscular injection, contains testosterone enanthate which is the oil-soluble ester of the androgenic hormone testosterone. Enanthate Injection is available as a colorless to pale yellow solution. Each mL contains 200 mg testosterone enanthate in sesame oil with 5 mg chlorobutanol as a preservative.
Study NCT03474029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifapentine daily for 6 weeks
Description: 600 mg of Rifapentine (RPT) given once daily (o.d., omni die) for 6 weeks (6wP).
Study NCT00758602 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: corticosteroids
Description: According to center's practice
Study NCT03474029 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifapentine and Isoniazid weekly for 12 weeks
Description: Rifapentine (RPT) 900 mg and isoniazid (INH) 900 mg given once-weekly for 12 weeks (3HP).\*~\*Dose adjustments based on patient's weight will be made according to ATS/CDC/IDSA guidelines.~RPT 900 mg once-weekly for persons weighing > 50 kg. For persons weighing \< 50 kg, the following doses will be given: weight > 25-32 kg - RPT 600 mg; weight > 32-50 kg - RPT 750 mg; + INH 15 mg/kg (round up to nearest 50 or 100 mg; 900 mg max).
Study NCT03474029 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifampin and Isoniazid daily for 12 weeks
Description: Rifampin (RIF) 600 mg and Isoniazid (INH) 300 mg given once-daily for 12 weeks (3HR)\*.~\*Dose adjustments based on patient's weight will be made according to ATS/CDC/IDSA guidelines.~RIF 600 mg daily for persons weighing > 50 kg. For persons weighing \< 50 kg, give 10 mg/kg daily; round up to nearest 50 or 100 mg; + INH 5 mg/kg daily (rounded up to nearest 50 or 100 mg; 300 mg max).